Sarcoma / 2015 / Article / Tab 3

Research Article

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Table 3

Outcomes of patients who withdrew from treatment with GDB for reasons other than toxicity or progression (AWD = alive with disease; NED = no evidence of disease; DOD = died of disease).

Time on treatment (months)Best response (RECIST)Maximal change of tumor (%)Treatment after GDBPathology from surgeryOutcome

63 y male with recurrent UPS of thigh1.4PR−39Resection of local recurrenceTreatment effect but viable tumorNED at 3.1 y
55 y female with recurrent UPS of thigh2.1SD0Limb perfusion and then surgery30–40% necrosis and fibrosisNED at 3.5 y
44 y female with angiosarcoma of vagina3.0PR−63Observation since biopsy showed no tumorNo tumor detectedNED at 1.3 y
55 y male with metastatic LMS3.5PR−31Resection of lung metastasesNecrosis and histiocytic infiltration (70%)DOD at 1.4 y
50 y female with large pelvic (nonuterine) LMS3.7SD−11Evaluated for surgery but unresectableN/AAWD at 2.5 y
39 y male with metastatic LMS4.2SD−15Radio-frequency ablation of liver metastasesN/ADOD at 2.4 y
69 y female with metastatic uterine LMS4.5SD−24Resection of pelvic metastasesPredominantly viableAWD at 2.2 y
40 y male with metastatic UPS4.6PR−32Resection of lung metastasesViable tumorDOD at 1 y
52 y male with metastatic angiosarcoma5.6PR−31Resection of lung metastasesViable but microscopic tumorAWD at 11 m
56 y male with metastatic pleomorphic liposarcoma7.0SD−30Resection of solitary bone metastasis>99% necrosis, rare viable cellsNED at 3.1 y
52 y male with metastatic LMS8.4PR−32Resection of lung metastases95% treatment effectAWD at 2.2 y
72 y female with metastatic UPS8.9PR−55Observation and then further chemotherapyN/AAWD at 2.6 y
57 y female with metastatic uterine LMS11.4PR−43Resection of lung metastases30% treatment effectDOD at 1.9 y

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.